Skip to content
Home > Staff & Recruitment > Page 3

Staff & Recruitment

KSF Personal Development Planning and Review Process is an ongoing process and integral part of practice. It links to the wide range of organisational and operational support mechanisms in place for staff throughout their career with NHSGGC.  

Induction

On commencing with NHSGGC, when changing roles or when returning from an extended period of absence, staff should receive an effective induction to support them in their role. This will enable objectives to be agreed and a Personal Development Plan to be developed to support their initial learning and application in practice. As such, it forms the initial stage of the ongoing KSF Personal Development Planning and Review process. Induction Portal

Staff Support and Wellbeing

The KSF PDP & Review process is a Person Centred approach. It links to ongoing wellbeing discussions with staff, provides a mechanism to discuss specific supports that staff may require and promotes open conversations for feedback highlighting recognition and appreciation of staff contribution. See the Staff Support and Wellbeing pages, HR Policies and Equality Diversity and Inclusion pages for further info on staff supports. 

Career Development

The ongoing KSF PDP & Review discussions can also be an opportunity to discuss staffs wider career development and to include planning around this. The Career and Development Planning Framework pages are designed to offer a wide range of information to help plan development activities for staffs current post and prepare for future roles as part of a career pathway.

Learning, Education and Training Service

The Learning, Education and Training Service offers a range of development opportunities for all staff from entry into post and throughout the span of their career. From formal qualifications to learning pathways, we will provide you with practical solutions tailored to your needs. This might be by gaining a work based qualification, attending a classroom session (where appropriate) or via digital learning.  

The Learning, Education and Training Catalogue outlines information on the wide range of tutor led and e-Learning courses that are available. Access to digital learning is flexible and resources can be accessed from mobile devices, work or home PCs at any time. You can also get support for learning through the NHSGGC Staff Bursary Scheme.

Organisational Development

The Organisational Development Pages also provide information on a range of interventions tools and resources to support ongoing development and learning including leadership development.

Professional Development

Individual professions will also have a range of resources available to support staffs ongoing professional learning and development.

Was this helpful?

Yes
No
Thanks for your feedback!
Referring a patient to the Genetic Clinic
Referral Guidance
Referring patients with a known clinical diagnosis for genetic testing

Please consider whether you could organise genetic testing yourself. We would be happy to see people with positive results thereafter if this is helpful. Sometimes, this allows relatives to seek genetic testing themselves, without the affected person needing to be seen in Clinical Genetics.

For available tests and referral criteria see the Scottish Genomics Test Directories for Rare and Inherited Disease and Cancer at Scottish Genomic Test Directories – Scottish Strategic Network for Genomic Medicine

Where you are referring a patient who does not have capacity to consent to genetic testing please ensure the relevant power of attorney is in place. Ideally, the person with power of attorney should also attend the appointment.

Where the patient lives distant from the QEUH site, is unable to travel, or has a life-shortening condition, please consider storing a genetic sample, so your patient could be offered a video appointment.

Information on how to send samples for storage and testing is found on our laboratory website Laboratory Genetics – NHSGGC

Referring patients with an uncertain clinical diagnosis for genetic testing

Please include results of all relevant clinical investigations unless these are on GGC clinical portal.

If there are affected relatives, please include as much information as possible, ideally their names, dates of birth and death, and address.

Referring patients planning a family to discuss reproductive options

If a couple have a personal or family history of a confirmed genetic condition, they can be referred to review their reproductive options/eligibility for Pre-Implantation Genetic Testing (PGT). These referrals can be made as for general referrals and will be triaged to the appropriate clinic.

If the couple become pregnant whilst on the waiting list they should contact our appointment team as soon as possible and their appointment may be expedited if appropriate.

Referrals of pregnant patients

If a pregnant couple with a family or personal history of a genetic condition wish to review their options for genetic testing during pregnancy please complete the prenatal referral form –https://forms.office.com/e/cH2vczJBbv. This pathway can also be used to make referrals related to abnormal scan findings. Referrals should be marked as urgent. Any queries about prenatal testing or referrals can be sent to ggc.wosprenatalteam@nhs.scot.

Where the genetic consultation will not alter the plans for this pregnancy, please make that clear in your referral. This will allow us to decide the urgency of the referral.

Referrals for Inherited Cardiac Conditions (ICC) Service

Referrals for the ICC Service can be made via Sci gateway or letter/email. These are reviewed and triaged on a weekly basis. For referrals from ICU after a cardiac arrest with unclear aetiology or suspected ICC, please consider sending a blood sample for DNA storage with the referral.

Information on how to send samples for storage and testing is found on our laboratory website Laboratory Genetics – NHSGGC

Referrals or queries for Cancer Genetics service

Referrals can be sent in the same way as for general referrals but if you are uncertain whether this is required, or want to know whether testing is indicated (which can often be requested by mainstream clinicians), please email the cancer genetics team on ggc.cancer.genetics@nhs.scot 

Referrals or queries from Community Paediatrics
Part 1: Children who should be considered for referral for assessment by a Clinical Geneticist

The chance of identifying a single gene disorder in a child with a neurodevelopmental disorder (NDD) is highest when there is:

  • Moderate or severe global developmental impairment
  • Severe language disorder (including non verbal)
  • Gross motor delay
  • Facial dysmorphism
  • Congenital anomalies
  • Abnormal growth eg microcephaly, macrocephaly, height &/or weight less than -2SD or more than +2SD, asymmetric growth
  • Other significant issues eg deafness, significant visual impairment, epilepsy, movement disorder, endocrine

Children with a NDD and any of the above should be considered for first line developmental screening blood tests to include chromosomal microarray and Fragile X syndrome and referral for assessment and consideration of further investigation by a Clinical Geneticist in one of their clinics where they will be seen and examined in person.

In the absence of any of the above, mild intellectual disability, autism spectrum disorder, ADHD, Tourette syndrome, hypermobility are more likely to be multifactorial with genetic +/- environmental contribution. Family history of other individuals with similar issues +/- mental illness in adulthood could support this. Chance of recurrence is significant but there can be considerable variability. These children do not require assessment by a Clinical Geneticist. The Multifactorial inheritance leaflet might be useful https://www.nhsggc.scot/clinical-genetics/.

Part 2: Referral with chromosomal microarray findings
Neurosusceptibility loci

The most common finding is a loss or gain involving a neurosusceptibility locus. These are associated with variable phenotypes and incomplete penetrance and can be considered as one of the many genetic factors contributing to multifactorial aetiology. There are leaflets available on the Unique Rare Chromosomal and Genetic Disorders website (www.rarechromo.org). Provided a child does not have any of the other issues listed above, with exceptions listed below, the family could be provided with the relevant leaflet and would not need to be referred for assessment by a Clinical Geneticist.

If parents would like to be tested for the variant or to discuss implications for a future pregnancy they can be referred for genetic counselling by a Genetic Counsellor who might offer them a telephone, video or in person appointment. When a neurosusceptibility locus variant is identified in the context of parental consanguinity there would be a higher chance of both parents carrying the variant and homozygous deletion or duplication (potentially with more severe consequences) in a subsequent pregnancy. Please consider referral for genetic counselling in these circumstances.

Exceptions who could be referred for assessment by a Clinical Geneticist include:

  • neurosusceptibility loci associated with specific medical issues
  • 1q21.1 microdeletion
  • 1q21.1 microduplication
  • 7q11.23 duplication (involving ELN)
  • 16p13.11 microduplication (involving MYH11)
  • 17q12 microdeletion (involving HNF1B)
  • neurosusceptibility loci which do not have Unique Disorder guides
  • deletions or duplications involving neurosusceptibility loci which are larger than typical or which overlap but have atypical breakpoints (the laboratory report will state if the deletion/duplication found has atypical features).

Leaflets are available for the following neurosusceptibility loci. These children do not require assessment by a Clinical Geneticist unless they have features listed in Part 1.

  • 2p16.3 (NRXN1) deletion
  • 15q11.2 microdeletion (Breakpoint 1-2)
  • 15q13.3 microdeletion
  • 16p11.2 microdeletion
  • 16p11.2 microduplication
  • 16p12.2 deletion
  • 16p13.11 microdeletion
  • 17q12 microduplication
  • 22q11.2 microduplication
  • 22q11.2 distal deletion syndrome
Variants of uncertain significance

Variants of uncertain significance are reported if they involve a developmental gene or if they are relatively large and involves a number of genes not known to be associated with NDD. In these circumstances there is not enough information available to determine if the copy number variant is relevant or not and therefore parents should not be advised to look on the internet as they are likely to come across irrelevant or misleading information.

In these circumstances further evidence can sometimes be obtained by testing parents for the variant usually via their GP practice or community hub. It is important to note on the request if the parent has neurodevelopmental, physical or health issues similar to their child. There is a patient information leaflet explaining why parental samples are required.

Once the lab has analysed both parents’ samples (if available) they will write their conclusion and issue an amended report. If the variant has been inherited from a parent who appears to be healthy and without evidence of NDD themselves this would suggest the variant is more likely to be benign and the child does not need to be referred for assessment by a Clinical Geneticist unless they meet criteria described in Part 1. Otherwise it is likely the report will suggest referral to Clinical Genetics.

Pathogenic variants

These are either recurrent variants with high penetrance such as 22q11 deletion (DiGeorge), 7q11.23  deletion (Williams), 1p36 deletion, 15q11.2q13 deletion (Prader Willi or Angelman), 15q11.2q13 duplication etc or rare (often unique to the family) variants which are likely to be pathogenic due to their size or involvement of 1 or more known developmental genes.

Please refer these to Clinical Genetics where they will be triaged to be seen either by a Clinical Geneticist or Genetic Counsellor.

Incidental findings

These are pathogenic or likely pathogenic variants which do not appear to explain the child’s phenotype but might have implications for their future health or reproductive risks (eg carrier of a common autosomal recessive disorder or female carrier of an X-linked disorder).

Please refer these patients to Clinical Genetics where they will be triaged to be seen either by a Clinical Geneticist or Genetic Counsellor.

Absence of heterozygosity (AOH)

Detection of AOH is not an indication for referral on its own however if the child fulfils any of the criteria in Part 1 they could be referred for assessment by a Clinical Geneticist.

Part 3: Children diagnosed with a single gene disorder

Any child who is suspected or has been identified as having a genetic disorder caused by variants in a single gene either clinically or on genetic or biochemical testing can be referred to Clinical Genetics where they will be triaged to be seen usually by a Clinical Geneticist for the initial appointment and for family follow up by a Genetic Counsellor thereafter if indicated. Single gene disorders might include Fragile X syndrome, Neurofibromatosis type 1, Rett syndrome, Tuberous Sclerosis Complex. Some metabolic or neurological disorders might require referral to Paediatric Neurology, Metabolic or another clinic for management of their symptoms but Clinical Genetics can coordinate referral and follow up of multisystem disorders and provide genetic counselling to parents and the wider family if required.

Fragile X results

Any child (male or female) found to have a full expansion in the FMR1 gene can be referred to Clinical Genetics.

If a premutation is identified, though it is unlikely to explain the child’s NDD, the child can be referred to assess if further investigations are indicated and to arrange genetic counselling for parents and the wider family.

If an FMR1 intermediate allele is identified it does not explain the child’s NDD and you might wish to refer them for assessment by a Clinical Geneticist if they fulfil criteria outlined in Part 1. There is a specific leaflet explaining implications of this finding mainly for future generations. If family members wish to be seen to discuss these they can be referred to Clinical Genetics where they will be contacted by a Genetic Counsellor.

Part 4: Advice regarding investigations, referrals or interpretation of results.

Please contact the Clinical Geneticist who runs your local Clinical Genetics clinic. If the need for a reply is urgent please contact ggc.genetics.referrals@nhs.scot where your query will be directed to the Duty Doctor for the day.

Referring unaffected children for genetic testing

We would usually offer testing to children when there is a family history of a condition that affects children during childhood.

Genetic testing is often only possible where there has been a gene variant identified in someone in the family, or where there is a living affected individual who can be tested.

Please provide the name, date of birth and address of the person with the gene variant, and or ask your patient to seek a copy of the genetic test report.

We would not usually offer genetic testing to children for adult onset conditions, and suggest they are advised to seek referral when they are adults.

Referring unaffected adults for predictive genetic testing based upon a family history

Genetic testing is often only possible where there has been a gene variant identified in someone in the family, or where there is a living affected individual who can be tested.

Please provide the name, date of birth and address of the person with the gene variant, and or ask your patient to seek a copy of the genetic test report.

If there is no known familial gene variant and all the affected people with that condition are now deceased, then it is unlikely that we could offer a genetic test to relatives.

However, for conditions such as cancer and cardiac conditions, even if genetic testing cannot be offered, the patient can be seen to evaluate their risk and for guidance on clinical screening.

How to make a referral

Please read the guidance above for the specific referral type before making a referral.

Health professionals can make an outpatient referral to Clinical Genetics via:

  • Sci Gateway
  • Post: Clinical Genetics, Level 2, Laboratory Medicine Building. QEUH, Govan Road, Glasgow, G51 4TF
  • Email: ggc.genetics.referrals@nhs.scot

Key information to include in the referral:

The details (name and D.O.B) of any related individuals who are already known to our service.

If the family have an existing reference number (e.g. 01234) please include this.

A way for us to contact YOU (the referrer) about the referral (ideally an e-mail address).

Please check that the patient’s phone number is correct.

How to confirm your referral has been received

Our genetic appointments do not show on TRAK. Patients will usually receive an acknowledgement letter upon receipt of their referral.

Please note that appointment waiting times vary between clinics, with some currently having waiting times of 1 to 2 years.

If you wish to check the status of a referral please contact the appointments team- ggc.genetics.referrals@nhs.scot

Patients NOT likely to need a referral
Cystic Fibrosis

Cystic Fibrosis (CF) is an autosomal recessive condition (https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/autosomal-recessive-inheritance/) with an estimated prevalence of ~1 in 3,000.  The most common associated complications are chronic lung disease, exocrine pancreatic insufficiency and male infertility.  It is estimated that ~1 in 20 to 1 in 25 of us are carriers of CF.  Being a carrier of CF is not expected to have any implications for your health, but it may have reproductive implications if both partners are found to carry CF variants.

Referral to Clinical Genetics:

We no longer see patients for CF carrier testing in the genetics clinic, unless there are additional concerns.  A couple who are both carriers of CF can be referred to Clinical Genetics if they are family planning and would like to discuss reproductive risks and options (e.g. preimplantation genetic testing and prenatal testing). If a patient has a family history of CF and is pregnant, they should be referred to Clinical Genetics to review their options.

Requesting CF Carrier Testing:

Non-genetic specialists (including GPs) can request CF carrier testing (5-10ml EDTA sample, sent to the Genetics lab).  It is imperative to state the name and details of the patient’s known affected relative. Further information on how to arrange carrier testing and interpretation of results can be found in this document – Cystic Fibrosis information sheet for GPs (link) or in the Scottish Genomic test directory ( NSD611-003.20-SSNGM-Test-Directory-Rare-Inherited-Disease-V5.pdf)

Genetic test request form can be found here: https://www.nhsggc.scot/downloads/routine-genetic-testing-request-form-2/. Alternatively, testing can be requested on Trakcare in ‘Lab – Adult’ using the request item ‘Germline molecular genetic analysis or storage’. Within the request, for ‘Testing Required’, select ‘Cystic Fibrosis/CFTR related condition’.  If ordering electronically please make sure to include the information about the relative known to be affected/a carrier as outlined above, as well as our reference/pedigree number if known.

Haemoglobinopathies

Haemoglobinopathies are a group of inherited blood conditions caused by alterations in the genes that produce haemoglobin. Haemoglobin is the substance inside our red blood cells which picks up oxygen as blood passes through the lungs and carries it to the rest of the body. How an individual is affected by a haemoglobinopathy condition can vary, with some conditions causes mild to moderate anaemia and others causing significant health issues, such as sickle cell anaemia and beta thalassemia major. Typically haemoglobinopathies are inherited in an autosomal recessive pattern (https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/autosomal-recessive-inheritance/). Carriers of alterations in the haemoglobin genes are typically well and do not experience and health problems because of being a carrier.

Genetics clinic referrals:

We no longer see carriers of haemoglobinopathies in the genetics clinic, unless a couple are both carriers of a haemoglobinopathy and are family planning. These couples can be referred to Clinical Genetics to review their reproductive risks and options.

Requesting haemoglobinopathy screening:

Non-genetic specialists (including GPs) can request a haemoglobinopathy screen which is a haematological blood test that can determine haemoglobinopathy carrier status. Testing can be requested via TrakCare and a 4ml EDTA (purple topped) sample should be collected.

If a patient is found to be a carrier of a haemoglobinopathy condition and they are considering pregnancy testing should also be arranged for their partner. As above, carrier couples can be referred to Clinical Genetics.

Further information about haemoglobinopathies can be found at – https://www.gov.uk/government/publications/handbook-for-sickle-cell-and-thalassaemia-screening/understanding-haemoglobinopathies.

Hereditary Haemochromatosis

We do not routinely see patients for Haemochromatosis diagnostic or carrier testing in the genetics clinic, unless there are additional concerns. 

Requesting Genetic Testing

Non-genetic specialists (including GPs) can request haemochromatosis carrier testing (5-10ml EDTA sample, sent to Laboratory Genetics). Guidance for testing and management of Haemochromatosis have been produced by the British Society for Haematology (BSH).

Acceptance criteria must be met and stated on the request form (see  The Scottish Genomic test directory, NSD611-003.20-SSNGM-Test-Directory-Rare-Inherited-Disease-V5.pdf)

Genetic test request form can be found here: https://www.nhsggc.scot/downloads/routine-genetic-testing-request-form-2/

*Before requesting this test, please check clinical portal to ensure that the patient has not been tested before. The results of these genetic tests will not change over time, and so repetition is of no value.

Non-healthcare professionals are not permitted to request genetic testing.

Hereditary Haemochromatosis information for clinicians

Haemochromatosis is a common inherited condition that affects how the body absorbs iron from your diet. It is more common in those with Northern European ancestry. 

Individuals with hereditary haemochromatosis experience a slow build-up of iron in the body over a number of years. Too much iron in the body is known as iron overload.  The excess iron can be stored in organs and tissues and lead to symptoms such as fatigue, joint pain, abdominal pain, shortness of breath and weight loss.  The condition can also affect the organs in the body such as the pancreas and the liver, which can lead to diabetes, liver cirrhosis, arthritis, cardiac problems and skin discolouration.

Treatments can include iron monitoring, chelation therapy, venesection to remove blood and reduce iron levels and changes to diet and lifestyle.

The genetics of Hereditary Haemochromatosis

Haemochromatosis is caused by variants in a gene called HFE gene.  We all have two copies of this gene as we inherit one from each of our parents.  For an individual to be affected with hereditary haemochromatosis, they must have alterations on both copies of the HFE gene. Carriers have an alteration on only one of their copies of the HFE gene. Therefore, for an individual to be affected by the condition, both parents must be carriers.

When both parents are carriers of Hereditary Haemochromatosis, in every pregnancy there is a:

  • 1 in 4 (25%) chance of having a baby who is not affected and not a carrier
  • 2 in 4 (50%) chance of having a baby who is a healthy carrier
  • 1 in 4 (25%) chance of having a baby who is affected by the condition

This is known as autosomal recessive inheritance.

Genetic testing for Hereditary Haemochromatosis 

Individuals who meet the testing criteria outlined the Scottish Genomic test directory (link can be found on the website) or who have a first-degree family member who is known to carry an HFE variant can have genetic testing arranged by non-genetics specialists (including GPs). Testing requires a 5-10ml EDTA sample sent to Laboratory Genetics with a genetic test request form (see website for link). Testing covers common alterations C282Y and H63D.

Genetic test results interpretation

No Variants detected

If a patient’s results showed they do not have the C282Y or H63D alterations in the HFE gene they are not likely to have hereditary haemochromatosis. We would not offer any further genetic testing or clinical follow up. If an individual is experiencing iron overload symptoms they should be investigated and treated as appropriate, but these are not likely to be caused by hereditary haemochromatosis.

Heterozygous for C282Y or H63D

If a patient has been found to be a carrier of HFE-related haemochromatosis they have an alteration on one copy of their HFE gene. Carriers of the condition are generally well and are unaffected with the condition. To be affected an individual must have genetic alterations on both their copies of the HFE gene, which leads to iron overload.

As carriers are generally well, they do not require any treatment or follow up therefore there is no further genetic testing that we would offer to your patient. If an individual is experiencing iron overload symptoms they should be investigated and treated as appropriate. However, these symptoms are not likely to be caused by HFE-carrier status.

Homozygous C282Y

Individuals who are found to be homozygous for the C282Y alteration in the HFE gene are generally affected by haemochromatosis and experience iron overload. Symptoms can be variable but generally include fatigue, joint paint, abdominal pain and weight loss. If left untreated it can lead to worsening symptoms including liver disease and diabetes. If an individual has raised iron levels, they should be referred to gastroenterology for management and follow up (see full management guidelines via link on website).

Compound Heterozygous C282Y/H63D

Individuals who are found to be compound heterozygous for the C282Y and H63D alterations in the HFE gene can experience iron overload. However, iron overload in these individuals happens at a slower rate than those homozygous for C282Y. Individuals can experience symptoms but are at a lower risk of serious complications such as organ failure. If ferritin and transferrin saturations levels are normal it is recommended that individuals have these check every 3 years. This can be done through the GP. If levels are raised individuals should be referred to Gastroenterology for management and follow up. 

Homozygous H63D

Individuals who are found to be homozygous for the H63D alteration in the HFE gene are unlikely to experience iron overload. Some individuals can experience iron overload and should have any symptoms investigated. This result does not confirm or exclude a diagnosis of haemochromatosis. If homozygous individuals do not have a raised iron level regular iron monitoring is not required. Genetic testing is not recommended for family members of homozygous individuals who do not have symptoms.

Implications for children

Testing Children – Carriers

If a patient is a carrier of haemochromatosis (heterozygous for H63D or C282Y) any children have a 1 in 2 (50%) chance of also being a carrier. Genetic testing can be carried out from the age of 16 via the GP practice. As mentioned, Carriers are generally well and do not experience any symptoms. If both parents are carriers there is a 1 in 4 (25%) chance any children will be affected. If any children are found to be affected, they should be referred to gastroenterology for follow up and management.

Testing Children – Affected

If a patient is affected with haemochromatosis any children that they have will be a carrier of the condition. This is because affected individuals have alterations in both copies of their HFE gene. We always pass on one copy of each of our genes to our children, so children of affected individuals will always inherit an altered copy of the HFE gene making them a carrier of haemochromatosis. If an affected individual’s partner is a carrier of haemochromatosis there is a 1 in 2 (50%) chance any children will be affected with the condition. Children can be tested from the age of 16 through their GP practice. If they are found to be affected, they should be referred to gastroenterology for management and follow up.

Implications for first degree family members

Parents and siblings of individuals who are carriers or affected by Hereditary Haemochromatosis can request genetic testing via their GP to clarify their carrier status. Partners of individuals who are affected or carriers can also seek testing via the GP. Results interpretation and management guidance as above.

Reproductive implications

If an individual is affected with Hereditary Haemochromatosis and their partner is a carrier, there is a 1 in 2 chance any children they have will be affected by the condition. If their partner is not a carrier any children, they have will all be carriers of the condition. Since Hereditary Haemochromatosis is an adult-onset condition with a number of management options genetic testing during pregnancy (prenatal testing) is unlikely to be offered. See above section about testing children.

If a couple are both carriers of Hereditary Haemochromatosis any children have a 1 in 4 chance of being affected and a 1 in 2 chance of being a carrier. As above prenatal testing is unlikely to be offered, and children can consider testing from the age of 16 via their GP.

Patient resources

Further information for patients can be found at the following links:

Further useful information about the condition can be found via the NHS Conditions website: Haemochromatosis – NHS (www.nhs.uk)

Requesting Genetic Testing

For available tests and referral criteria see the Scottish Genomics Test Directories for Rare and Inherited Disease and Cancer at Scottish Genomic Test Directories – Scottish Strategic Network for Genomic Medicine

Information on how to send samples for storage and testing is found on our laboratory website Laboratory Genetics – NHSGGC

Was this helpful?

Yes
No
Thanks for your feedback!

Below are the approved Minutes of Meetings of Area Partnership Forum Workforce & Strategy meetings from November 2024 onwards. To access Minutes of Meetings prior to November 2024, please contact the APF Administrator at kirstin.mckenzie@nhs.scot.

Area Partnership Forum Minutes (Strategy) April 2026

80.30 KB 50 Downloads
27/05/2026
Download

Area Partnership Forum Minutes (Workforce) – April 2026

107.43 KB 106 Downloads
13/05/2026
Download

Area Partnership Forum (Workforce) February 2026

104.24 KB 186 Downloads
23/04/2026
Download

Area Partnership Forum (Strategy) – December 2025

80.67 KB 179 Downloads
23/04/2026
Download

APF Minutes (Workforce) – January 2026

105.32 KB 424 Downloads
18/03/2026
Download

Area Partnership Forum Minutes (Workforce) – November 2025

106.78 KB 851 Downloads
19/01/2026
Download

APF Minutes (Strategy) – September 2025

79.01 KB 998 Downloads
17/12/2025
Download

Area Partnership Forum Minutes (Workforce)- October 2025

109.94 KB 1089 Downloads
18/11/2025
Download

APF Minutes (Workforce) – August 2025

107.17 KB 1133 Downloads
28/10/2025
Download

APF Minutes (Strategy) – June 2025

301.77 KB 1539 Downloads
18/09/2025
Download

Was this helpful?

Yes
No
Thanks for your feedback!

Was this helpful?

Yes
No
Thanks for your feedback!

Engaging with staff side at the earliest opportunity is crucial for fostering a collaborative and supportive work environment, whether at a local level or boardwide. Early engagement ensures that staff members feel valued and heard, which in turn can lead to increased morale and productivity. By addressing concerns and ideas promptly, management can build trust and avoid potential conflicts, creating a seamless flow of communication. Furthermore, involving staff in decision-making processes from the outset cultivates a sense of ownership and accountability, which is essential for the successful implementation of policies and initiatives.

Please select the relevant area below with regards to engaging with the Area Partnership Forum (APF).

If further assistance is required, please contact the APF Administrator at kirstin.mckenzie@nhs.scot.

Board Partnership Documents

This Partnership Agreement has been developed jointly by the Board and the Trades Unions and Professional Organisations representing staff. The Agreement is designed to ensure staff are effectively involved in influencing the shape and implementation of decisions that affect their work, and offer managers the means through which staff views can be considered before taking the decisions for which they are responsible.

This Facilities Agreement, developed jointly by the Board and the Trade Unions and Professional Organisations representing staff, has been designed to establish a formal policy and procedure on trade union/professional organisation facilities. In developing the agreement cognisance was taken of the legal requirements placed on the Board, the Staff Governance Standard, and Partnership Information Network Policy and Practice.

How to Engage with Staff Side & the Area Partnership Forum

Prior to bringing papers to the APF please ensure that you have followed steps 1-2 (Boardwide or Local) of the Partnership Engagement Process (3rd link below). Papers will not be accepted for the Forum if staff side have not been engaged.

Seeking staff side representation differs depending on the Group you are requiring staff side input for. If you have a local group, please seek staff side representation via your local Staff Partnership Forum Staff Side Co-Chair and/or Deputy. For all Board & Corporate Groups, APF staff side representation should be sought via the link below.

How to Seek APF Staff Side Representation for Your Group. (Please note above)

How to Engage & Bring Papers to the Area Partnership Forum (Workforce & Strategy) (Both Boardwide & Local)

APF & Corporate Staff Partnership Forum Templates

APF Cover Template (to be used with APF Paper template below)

APF Paper Template (to be used with APF Cover template above)

Corporate Staff Partnership Forum Cover Template (to be used with CSPF template below).

Corporate Staff Partnership Forum Paper Template (to be used with CSPF Cover template above.

Was this helpful?

Yes
No
Thanks for your feedback!
How to Engage with Staff Side,
Area Partnership Forum
and Templates
Corporate Staff Partnership Forum
Minutes of
APF Meetings
(Workforce & Strategy)
Area Partnership Forum Meeting Dates 2026
Web Links
and
Contacts

The Area Partnership Forum (APF) serves as a pivotal platform for collaborative decision-making and strategic planning within NHS Greater Glasgow and Clyde.

Its primary role is where the NHS Board and 14 recognised Trade Union and professional organisations work together to improve health services for the population of Greater Glasgow and Clyde, and to engage in negotiations with the aspiration of making NHSGGC an exemplar employer.

The Area Partnership Forum will be a powerful enabling force to:

  • Inform thinking around priorities on health issues.
  • Inform and test delivery and implementation plans in relation to national strategies.
  • Advise on workforce planning and development.
  • Advise on the delivery of the staff governance legislation.
  • Promote equality and diversity.
  • Promote and Engage in Partnership Working.

Providing a structured environment for dialogue, the Forum ensures that all voices are heard and contributing to the formulation of policies that reflect the collective interests of the community. The remit of the Area Partnership Forum includes identifying priorities, allocating resources effectively, monitoring progress, and evaluating outcomes to ensure continuous improvement. By promoting transparency, accountability, and inclusivity, the Area Partnership Forum plays a crucial role in driving sustainable development, and improving the quality of life for residents within the area.

Forum meetings are divided between meetings concerned with a broad strategic agenda and those with an agenda constructed around matters more specific to employee relations. Meetings are Co-Chaired by the Chief Executive, Employee Director and the Director of Human Resources and Organisational Development. The Forum provides formal reports to the Staff Governance Committee of the NHS Board.

The terms of reference for the Area Partnership Forum can be found within the Board Partnership Agreement.

Prof Jann Gardener
Chief Executive & APF Strategy Co-Chair
Portrait image of Ann Cameron-Burns, Employee Director
Anne Cameron-Burns
Employee Director & APF Strategy & Workforce Co-Chair
Staff Placeholder photo of Natalie Smith, Interim Director of Human Resources & Organisational Development at NHSGGC
Natalie Smith
Interim Director of Human Resources and Organisational Development & Co-Chair APF Workforce

Was this helpful?

Yes
No
Thanks for your feedback!

Civility Saves Lives (CSL) is about how we treat each other at work. The CSL campaign aims to promote positive working relationships and raise awareness about how our behaviour with colleagues can have a direct impact on patient care and outcomes, and staff experience and wellbeing.

It is the responsibility of us all to work together and make conscious decisions about how we behave, so that everyone feels respected, valued, supported and empowered to carry out their work.

The campaign is grounded in research showing that even small acts of rudeness can significantly impact staff wellbeing, team performance, and patient safety.

You can contact your local Organisational Development Advisor to discuss or find out a bit more or visit our SharePoint where you can see the list of groups, contacts, Leads, and watch information videos and download copies of posters.

You can also find more information and read the FAQs.

World Kindness Day (13 November)

This year, NHSGGC is celebrating World Kindness Day on Thursday 13 November!

We encourage you to get involved on the day, either by visiting stalls or attending events at your site (more information coming soon!), celebrating with colleagues, or even just making time for a cup of tea and a chat.

Visit the World Kindness Day page for more information, six-week challenge activities, and the chance to nominate your colleagues to be recognised on the day.

Was this helpful?

Yes
No
Thanks for your feedback!


Supervision provides a safe place for reflection for all AHPs, regardless of band or role (registered staff and health care support workers).

For further information and support contact, Jane Dudgeon, NHSGGC AHP Practice Education Manager

Email: jane.dudgeon@ggc.scot.nhs.uk

Was this helpful?

Yes
No
Thanks for your feedback!

This year the Chair, Dr Lesley Thomson KC, presented the Chair’s Awards of Excellence which recognise outstanding achievement, expertise and dedication in patient care. As with all our awards, they celebrate the incredible efforts of our wonderful staff.

The Celebrating Success Event was held on Wednesday 28th May 2025.

The winners were announced live on the night on our social media channels (follow the #ggcawards tag).

You can find out who the winners were and also view their photos and videos below.

Congratulations to all our winners!

Chair Award of Excellence Winner – The Fetal-Genetics Group at the Queen Elizabeth University Hospital

The Fetal-Genetics Group at the Queen Elizabeth University Hospital has been established to improve the experience for patients and families planning or undergoing a pregnancy where there is a known family history of a genetic condition and/or pregnancy loss.

The Fetal-Genetics Group combines the skills of Consultant Obstetricians, Specialist Midwives, Consultant Geneticists, Genetic Counsellors and Clinical Scientists to provide a truly multi-disciplinary approach that allows the most appropriate support and information and any genetic testing to be made available to this group of patients at the earliest opportunity and throughout their pregnancy and beyond.

Chief Executive Award of Excellence Winner – Scottish Epilepsy Register

The Scottish Epilepsy Register has been developed under the leadership of NHSGGC Consultant Neurologist Dr Craig Heath and Johnathan Todd, Head of Information Management. Epilepsy is one of the most common neurological conditions, with an estimated 55,000 people living with it in Scotland. The Scottish Epilepsy Register uses routine health data, collected via a clinical dashboard, to provide an alert to healthcare professionals following a key adverse event. Its main aim is to reduce excessive mortality and morbidity in epilepsy and to improve access to care and outcomes in people living with the condition. 

As part of the project, key pieces of clinical information are collected from other health boards which will be used to create a Scottish National Audit Programme for Epilepsy, allowing trends and outcomes to be tracked and monitored. Once fully established, the methodology could be applied to other chronic neurological diseases to improve disease recognition and management.

Was this helpful?

Yes
No
Thanks for your feedback!

The William Cullen Prize for Excellence In Teaching and the William Cullen Prize for Service Innovation are awarded in collaboration with the Royal College of Physicians in Edinburgh.

The Celebrating Success Event was held on 28th May 2025.

The winners were announced live on the night on our social media channels (follow the #ggcawards tag).

You can find out who the winners were and also view their photos and videos below.

Congratulations to all our winners!

William Cullen Prize for Innovation Winner – Red Star Fracture Liaison Service based in the South Sector, led by Dr Maria Talla

The Fracture Liaison Service (FLS) aims to identify and treat patients over the age of 50 who have sustained a fragility fracture, and refer them for an assessment of their bone health in order to reduce their risk of subsequent fractures.

Dr Talla and her team have partnered with RedStar to develop a web-based clinician dashboard system known as RedStar FLS.

The dashboard has significantly reduced the time it takes for the Fracture Liaison Service to identify a patient who has had a fragility fracture, from an average of 15 months to 3 days. This allows prompt assessment and treatment initiation. An automated audit tool has been built into the dashboard and shows that the NHS GGC South Sector FLS is outperforming national FLS standards across the UK.

William Cullen Prize for Education Winner – Intensive Care Medicine in the Glasgow Royal Infirmary

Over the last year, this department has demonstrated an excellent profile in training all grades of doctors, from Foundation to Specialty resident doctors, and has been recognised in providing this in the Scottish Trainee Survey.

The department led by Dr Barbara Miles and her team performs well in many domains, and in particular in important areas such as induction and handover, creating a positive educational environment that is clearly appreciated by the doctors who work there.  There is a focus on learning through weekly MDT simulation scenarios and structured learning is provided in weekly education slots on site that can also be accessed remotely.

Was this helpful?

Yes
No
Thanks for your feedback!